Gefitinib: Phase II and III Results in Advanced Non-Small Cell Lung Cancer

Karen Kelly, Steven Averbuch

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Several novel biologic agents have been designed to specifically inhibit different aspects of tumor growth and progression. The epidermal growth factor receptor has a pivotal role in tumor biology and thus is an important anticancer target. Gefitinib is an orally active epidermal growth factor receptor tyrosine kinase inhibitor that blocks signal-transduction pathways implicated in the proliferation and survival of cancer cells. Clinically meaningful antitumor activity, symptom relief, and a good tolerability profile have been shown in phase II trials of gefitinib monotherapy in patients with recurrent non-small cell lung cancer. Clinical trials are ongoing to investigate further applications of this novel agent for the treatment of non-small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)93-99
Number of pages7
JournalSeminars in Oncology
Volume31
Issue number1 SUPPL. 1
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Neoplasms
Biological Factors
Protein-Tyrosine Kinases
Signal Transduction
Cell Survival
Clinical Trials
Growth
gefitinib
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Gefitinib : Phase II and III Results in Advanced Non-Small Cell Lung Cancer. / Kelly, Karen; Averbuch, Steven.

In: Seminars in Oncology, Vol. 31, No. 1 SUPPL. 1, 02.2004, p. 93-99.

Research output: Contribution to journalArticle

Kelly, Karen ; Averbuch, Steven. / Gefitinib : Phase II and III Results in Advanced Non-Small Cell Lung Cancer. In: Seminars in Oncology. 2004 ; Vol. 31, No. 1 SUPPL. 1. pp. 93-99.
@article{373c78d82aa4446786408a3c5fac7a6f,
title = "Gefitinib: Phase II and III Results in Advanced Non-Small Cell Lung Cancer",
abstract = "Several novel biologic agents have been designed to specifically inhibit different aspects of tumor growth and progression. The epidermal growth factor receptor has a pivotal role in tumor biology and thus is an important anticancer target. Gefitinib is an orally active epidermal growth factor receptor tyrosine kinase inhibitor that blocks signal-transduction pathways implicated in the proliferation and survival of cancer cells. Clinically meaningful antitumor activity, symptom relief, and a good tolerability profile have been shown in phase II trials of gefitinib monotherapy in patients with recurrent non-small cell lung cancer. Clinical trials are ongoing to investigate further applications of this novel agent for the treatment of non-small cell lung cancer.",
author = "Karen Kelly and Steven Averbuch",
year = "2004",
month = "2",
language = "English (US)",
volume = "31",
pages = "93--99",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 1",

}

TY - JOUR

T1 - Gefitinib

T2 - Phase II and III Results in Advanced Non-Small Cell Lung Cancer

AU - Kelly, Karen

AU - Averbuch, Steven

PY - 2004/2

Y1 - 2004/2

N2 - Several novel biologic agents have been designed to specifically inhibit different aspects of tumor growth and progression. The epidermal growth factor receptor has a pivotal role in tumor biology and thus is an important anticancer target. Gefitinib is an orally active epidermal growth factor receptor tyrosine kinase inhibitor that blocks signal-transduction pathways implicated in the proliferation and survival of cancer cells. Clinically meaningful antitumor activity, symptom relief, and a good tolerability profile have been shown in phase II trials of gefitinib monotherapy in patients with recurrent non-small cell lung cancer. Clinical trials are ongoing to investigate further applications of this novel agent for the treatment of non-small cell lung cancer.

AB - Several novel biologic agents have been designed to specifically inhibit different aspects of tumor growth and progression. The epidermal growth factor receptor has a pivotal role in tumor biology and thus is an important anticancer target. Gefitinib is an orally active epidermal growth factor receptor tyrosine kinase inhibitor that blocks signal-transduction pathways implicated in the proliferation and survival of cancer cells. Clinically meaningful antitumor activity, symptom relief, and a good tolerability profile have been shown in phase II trials of gefitinib monotherapy in patients with recurrent non-small cell lung cancer. Clinical trials are ongoing to investigate further applications of this novel agent for the treatment of non-small cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=1242273864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1242273864&partnerID=8YFLogxK

M3 - Article

C2 - 14981586

AN - SCOPUS:1242273864

VL - 31

SP - 93

EP - 99

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 1

ER -